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In sepsis, reactive oxygen species (ROS) production is increased. This process takes place mainly within the electron transport
chain. ROS production is part of the pathophysiology of multiple organ failure in sepsis. Succinate yields Dihydroflavine-
Adenine Dinucleotide (FADH2), which enters the chain through complex II, avoiding complex I, through which electrons are
lost. The aim of this work is to determine if parenteral succinate reduces systemic ROS production and improves kidney
function. Rats with cecal ligation and puncture were used as model of sepsis, and 4 groups were made: Control group; Succinate
group, which only received parenteral succinate; Sepsis group; and Sepsis which received parenteral succinate. Systemic ROS are
measured 24 hours after the procedure. Rats subjected to cecal puncture treated with succinate had less systemic ROS than
Septic untreated rats (p = 0 007), while there were no differences in creatinine levels (p = 0 07). There was no correlation
between creatinine and systemic ROS levels (p = 0 3). We concluded that parenteral succinate reduces ROS levels, but it does
not reduce creatinine levels. Since there is no correlation between both levels, the processes would not be related.
1. Introduction
Sepsis is a pathology whose incidence is increasing, with
a mortality rate that, according to a recent report, can
reach 40% [1]. Its mortality rate is related to multiple
organ failure [1].
Triggering mechanisms of organ failure appear to be
multiple. Oxidative stress seems to be one of these triggering
mechanisms. There are different definitions of oxidative
stress, but the most common and descriptive one is the
imbalance between the production of reactive oxygen species
(ROS) and cellular antioxidant capacity, which can poten-
tially damage cells and destroy tissue [2].
Reactive oxygen species are a group of molecules which
include oxygen radicals, such as superoxide (O2
⋅−), hydroxyl
(OH⋅), peroxide (RO2
⋅), and alkoxide (RO⋅), as well as nonra-
dicals that are oxidizing agents or that quickly become radi-
cals, such as hypochlorous acid (HOCl), singlet oxygen
(1O2), and hydrogen peroxide (H2O2) [3]. On the other hand,
there are also reactive nitrogen species (RNS), both radical
and nonradical, such as nitric oxide (NO), peroxynitrite
(ONOO−), and nitrogen dioxide (NO2
⋅) [4, 5].
Over the last few years, there have been a large num-
ber of studies that describe oxidative stress in patients
with sepsis, with evidence of ROS production, related
damage, and antioxidant depletion [6]. Serious conditions
are characterized by hyperinflammation, cellular immune
dysfunction, oxidative stress, and oxidative mitochondrial
dysfunction [7]. An activated immune system and mito-
chondrial dysfunction are the two most powerful sources
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 1928945, 6 pages
https://doi.org/10.1155/2018/1928945
of reactive molecular species. It has been proven that
sepsis is characterized by an increase in the production
of ROS, as well as reactive nitrogen species (RNS), both
in circulation (produced by cells of the immune system
and the endothelial system) and tissue (due to mitochon-
drial dysfunction and the modification of the antioxidant
state) [4, 5].
When antioxidant defenses are outnumbered, oxidative
stress, which can significantly damage lipids, proteins, and
nucleic acids, occurs both within the mitochondria and the
rest of the cell [2, 6, 7].
During sepsis, most ROS are produced in the mitochon-
dria. It is believed that this is due to the electron loss that
takes place when they are passed from complex I to complex
III of the mitochondrial electron transport chain. On the
other hand, the uncoupling of the chain also takes place
between complex I and complex II [8]. Electrons that reduce
complex I come from reduced coenzymes, Nicotinamide
adenine dinucleotide (NADH+H+), while Dihydroflavine-
Adenine Dinucleotide (FADH), which comes from succinate
oxidation in the Krebs cycle, is oxidized in complex II, with
electrons entering through the said complex [8]. In different
studies, succinate has improved oxygen consumption in sep-
tic rat muscle [8], prolonging the survival of the said septic
animals [9] and improving the hepatic metabolic profile [10].
The objective of this study is to observe whether the
administration of intraperitoneal succinate to rats subjected
to cecal ligation and puncture reduces ROS production and
improves sepsis-induced kidney failure.
2. Materials and Methods
2.1. Animals. Male Sprague Dawley rats of 200 grams of
average weight adapted to 12 h light cycles for 7 days and
fed ad libitum at a room temperature of 24°C were used.
The experiments were approved by the IACUC (Institutional
Animal Care and Use Committee) of the Faculty of Medicine
of the University of Buenos Aires, Argentina.
2.2. Groups. Four groups were formed: (1) Control group; (2)
Succinate group, to which intraperitoneal succinate was
administered 2 hours before initiating the surgery of groups
3 and 4 and 2 hours before the taking of the sample; (3) Cecal
Puncture group, on which the procedure described in the
following item was performed; (4) Cecal Puncture and
Succinate group, to which succinate was administered 2
hours before the surgery and 2 hours before the taking of
the sample. 24 hours passed between the surgery and the tak-
ing of the sample (Figure 1).
2.3. Cecal Ligation and Puncture. The procedure was per-
formed under sedation and anesthesia with 100mg/kg of
intraperitoneal Ketamine and 2.5mg/kg of intraperitoneal
Xylazine. In accordance with the technique described in
literature [11–16], a midline laparotomy was performed,
the cecum was identified, and 1 cm was ligated. Both sides
of the ligated cecum were punctured with a 25× 8 needle,
and subsequently, a layered ligation of abdominal wall was
performed. A single dose of 30mg/kg of intraperitoneal
ceftriaxone and 25mg/kg of clindamycin was adminis-
trated and then 20ml/kg of intraperitoneal NaCl 0.9%.
2.4. Succinate Solution. Intraperitoneal succinate solution
was administrated on groups 2 and 4, according to the
flow chart specifications. 5mmol/kg of intraperitoneal
succinate 0.4M solution was administered. Solution was
prepared from succinic acid (Sigma Chemical Co.), neu-
tralized with NaOH, and sterilized by filtration.
2.5. Procedure. Intraperitoneal succinate solution was admin-
istered to rats of groups 2 and 4. Two hours later, cecal liga-
tion and puncture was performed to rats of groups 3 and 4.
24 hours later, another administration of intraperitoneal
succinate solution was performed to rats of groups 2 and 4.
Two hours later, blood samples were taken, and rats were
sacrificed after that (Figure 1).
2.6. Blood Sample. A blood sample was taken through cardiac
puncture under anesthesia with 100mg/kg of intraperitoneal
Ketamine and 2.5mg/kg of intraperitoneal Xylazine, and the
animal was later euthanized. Blood was centrifuged in a dry
tube at 3000 rpm (900g) for 5 minutes. Then, the serum
was separated and frozen at −75°C until measurement.
2.7. Measurement of Systemic ROS. The measurement of
systemic ROS was taken using 2′,7′ dichlorofluorescein-
diacetate (DCFH) (Sigma Chemical Co.). 12μl of serum
was incubated for 10 minutes in 1000μl of TE buffer,
and 10μl of NaOH was added to hydrolyze the diacetate
and, thus, activate the dichlorofluorescein. Emitted
4 groups (5 rats each group)
Group 1 − control 5 mmol/kg of IP
0.4 M succinate
solution
Group 2 − succinate
Group 3 − cecal ligation
Group 4 − cecal ligation + succinate
2 hs 2 hs24 hs
Succinate
administration
Surgery Succinate
administration
Surgery
blood sample
Figure 1: Procedure flow chart. Surgery was made only in groups 3 and 4. Succinate was administered in groups 2 and 4.
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fluorescence was measured with Jasco FP770 equipment.
An emission spectrum between 500 and 550 nm was used
with each sample. The expressed value is the mean of the
emission at 525nm.
2.8. Creatinine Levels. Blood sample was taken as described
above. The measurements were processed on a Vitros
5600 Ortho Clinical Diagnostics analytical platform, using
the dry chemistry method. Average results are expressed
in mg/dl.
2.9. Statistical Analysis. The Statistix 7.0 program was used.
The Student t-test to highlight differences between 2 groups
and the ANOVA test for 4 groups were performed. A positive
of p < 0 05 was used. Pearson test was used to highlight
correlation between 2 variables.
3. Results
DCFH average emissions were as follows: group 1 (0.0332
(SD=0.008)); group 2 (0.0352 (SD=0.011)); group 3
(0.0759 (SD=0.037)); and group 4 (0.0598 (SD=0.006))
(Figure 2). There were significant differences among the 4
groups (ANOVA test p = 0 016). Furthermore, there were
significant differences between groups 1 and 3 (p = 0 007)
and groups 3 and 4 (p = 0 007). No differences were found
between groups 1 and 4 (p = 0 3).
Average serum creatinine levels were as follows: group1
(0.39mg/dl (SD=0.07)); group 2 (0.4mg/dl (SD=0.07));
group 3 (0.54mg/dl (SD=0.08)); and group 4 (0.6mg/dl
(SD=0.2)) (shown in Figure 3). There were also significant
differences among the 4 groups (ANOVA test p = 0 035),
but there were no differences between groups 1 and 3
(p = 0 33) or groups 3 and 4 (p = 0 07). However, there were
differences between groups 1 and 4 (p = 0 037). Finally, there
were no differences in serum lactate levels among the 4
groups (ANOVA test p = 0 3).
On the other hand, there was no correlation in creatinine
levels among the 4 groups (rho=0.24; p = 0 3) (Figure 4).
4. Discussion
It can be seen in this study that systemic ROS levels were ele-
vated in septic rats, and administering parenteral succinate
reduced ROS production in septic animal. Also, succinate
did not reduce creatinine levels. At last, creatinine levels did
not correlate with DCFH levels.
This study is innovative, as systemic ROS, or serum ROS,
were measured in sepsis. Literature describes the presence of
ROS at the tissue level and associates tissue damage with the
presence of these molecules. In other studies, we measured
the presence of ROS in yeast in the presence of Menadione
[17]. In the study, we used the DCFH technique to measure
the presence of molecules in the serum. The DCFH technique
measures ROS, mainly at the intracellular level [18–21], since
the fluorophore (Dichlorofluorescein Diacetate) needs diace-
tate to be separated in order to be activated and emit a signal
at 525nm. The separation of the diacetate takes place inside
the cells due to the presence of esterases. This technique is
also described for measurements in extracellular fluids. The
technique varies in that, during incubation, NaOH is added
to separate the diacetate without the need for esterases. This
technique has already been described in literature [21–24].
It is known that ROS at the tissue level damage pro-
teins, cell membranes, and nucleic acids. This damage can
lead to cell death via apoptosis, which has been described
many times. This description is mainly at an experimen-
tal level in cell lines or experimental models and at the
tissue level. In literature, the presence of systemic ROS
in an animal model of sepsis is described, but they are
measured with the TBARS technique, and they are also
increased in the model, but their presence is not associ-
ated with organ failure markers [25]. Furthermore, the
total antioxidant capacity was measured in a study on
septic patients, in which those who did not survive had
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Figure 2: Serum ROS levels. DCFH emission levels. ANOVA test showed differences between groups (p = 0 016). There were significant
differences between groups 1 and 3 (p = 0 007) and groups 3 and 4 (p = 0 007). No differences were found between groups 1 and 4 (p = 0 3).
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a higher total antioxidant capacity and, in turn, this was
a marker of 30-day mortality [26]. In this study, systemic
ROS were not measured, and their presence was not
associated with organ failure markers [26]. In a different
study, ROS in whole blood were measured in septic
patients with DCFH. It was shown that patients with a
SOFA score greater than 7 had higher ROS levels [27].
In vivo, ROS are produced through different pathways, in
different cells and in different amounts. Phagocytic cells
are the main producers of ROS in acute illness, as a
component of immune defenses which its objective is
destroying microorganisms [2]. Under physiologic condi-
tions, there is a continuous mitochondrial production of
ROS and more precisely in the electron transport chain,
which produces 90% of these molecules [3]. There is a
clear relation between inflammatory molecules and oxida-
tive stress levels though [2, 7].
This study is also innovative, as systemic ROS levels were
reduced in septic rats with succinate, a Krebs cycle interme-
diate, with no changes in nonseptic rats. This could be due
to the fact that the electron transport chain is not affected
in nonseptic rats; the effects of the drug are not the same as
those seen in septic rats.
Chouchani et al. [28], in their work, express that there
is succinate accumulation during hypoxia-reoxygenation.
Through several tests, they show that glucose, palmitate,
glutamine, and GABA do not contribute to the
accumulation. Instead, the origin of the accumulation is
fumarate. The reactions that carries out from the formation
of citric acid to succinate are all with negative standard
free-energy difference (ΔG°′), which means that they are
spontaneous. Instead, the reactions go after succinate are
with ΔG°′=0 (from succinate to fumarate) or positive ΔG
°′, which means that it is not spontaneous. The reaction
from succinate to fumarate will go in diverse ways depend-
ing on the concentration of the substrates [29]. During
hypoxia, electron transport chain is stopped because there
is no final substrate, oxygen. There is no reoxidation of
NAD+ and FAD, and anaerobic glycolysis occurs,
producing lactate. Also, as there is no NAD+ and FAD,
β-oxidation is also stopped, so there will be no acetyl-
CoA for Krebs. But hypoxia-reoxygenation is not the only
physiopathological issue in sepsis.
In sepsis, other mechanisms take place in the mito-
chondria. Several studies showed that there is low activity
in the electron transport chain, in different complex. Lor-
ente et al. showed lower activity of complex IV in plate-
lets of septic patients [30], while Brealey et al. [31]
showed a lower activity in complex I, while in complexes
II, III, and IV, there was no difference. The same group,
also, showed that complex II/III activity remained
unchanged in both the muscle and the liver of septic rats
[32]. Also, both skeletal muscle and liver complex I activ-
ity fell with increasing disease severity in septic rats [32].
In sepsis, electron transport chain activity and mito-
chondrial respiration are decreased, shown by the lower
levels in oxygen consumption and the decrease in ATP
levels and ATP/ADP ratio [33]. Also, several metabolic
pathways have been proposed as targets in sepsis, such as
the pathways that regulate glycolysis or fatty acid metabo-
lism, sources of Acetyl-coA, substrate of Krebs cycle [33].
Succinate has shown to improve mean survival time in sep-
tic rats with succinic acid infusion [9, 10]. Also, mitochon-
drial respiration was augmented in moderately-to-severely
septic animals, shown by the recovery of oxygen consump-
tion [8]. In the hepatocytes of lipopolysaccharide-injected
rats, the infusion of succinate improved the plasma concen-
tration of free fatty acids and B-hydroxybutyrate, the liver
ATP content, and the oxidation of D-glucose as well as
the pyruvate/lactate ratio [10].
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Figure 3: Serum creatinine levels. ANOVA test showed differences between groups (p = 0 0353).
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Several attempts have been made to reduce oxidative
stress in septic patients, most of them with inconclusive
results [34–37], being parenteral succinate an alternative
therapeutic option.
All these results might show that succinate in sepsis
can improve systemic ROS levels restoring the electron
transport chain, but this does not improve renal function
measured with creatinine levels. Also, there is no correla-
tion between systemic ROS and creatinine levels, indicat-
ing that ROS production and kidney damage are not
linked. At last, we showed [38] that septic patients in the
ICU do not have more ROS in the bloodstream than
healthy controls, and those patients who died in the ICU
do not have more systemic ROS than those who survived.
In this study, no correlation between systemic ROS
levels and creatinine was found. Sepsis is the most common
cause of kidney failure in the ICU [39]. This can be a
pathophysiologic mechanism of distant injury in sepsis or
a severity marker of the disease. Septic rats showed higher
creatinine levels, which were not reduced with the adminis-
tration of succinate. This can be due to the fact that the
uncoupling of the electron transport chain and the produc-
tion of ROS are not part of the pathophysiology or due to
the fact that creatinine is a late marker of kidney injury,
and the duration of the test was not enough to show
improvement. There are other earlier and more accurate
biomarkers of kidney injury, such as NGAL, which is not
routinely used yet [40–42]. Therefore, we chose creatinine
as a marker of kidney injury.
The question that needs to be solved is that do ROS cause
tissue damage or just molecules that show that mitochondrial
processes are not working correctly. More studies are needed
to solve this question.
5. Conclusions
Parenteral succinate reduces systemic ROS levels, but it does
not reduce serum creatinine levels. Further studies are
needed to understand this drug’s mechanism of action.
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